deucravacitinib
bms
[' psa', 'ease,(-please),(-disease),(-incrrease),(-decrease)', '#1598', 'deucra']
mease et al. tyk2i deucravacitinib in psa. phase 2 rct 52 week results. pasdas, dapsa efficacy maintained through week 52. no new safety concerns. #acr22 abstr#1598 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC